# To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

> **NCT01495221** · PHASE4 · COMPLETED · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 9 (actual)

## Conditions studied

- AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

## Interventions

- **DRUG:** Alfilbercept

## Key facts

- **NCT ID:** NCT01495221
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495221, "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01495221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*